A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of PQR309

Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of advanced solid tumor for which no therapy of proven efficacy is available. * Age ≥ 18 * Evidence of tumor progression with measurable or evaluable disease. * Use of adequate contraceptive measures for male patients. * Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-1. * Signed informed consent. Exclusion Criteria: * Concomitant anticancer therapy (e.g., chemotherapy, radiotherapy, hormonal, immunotherapy, biological response modifier, signal transduction inhibitors) * Patients with a history of myocardial infarction or coronary artery bypass within the last 3 years. * Patients with severe/unstable angina, coronary/peripheral arterial bypass, symptomatic congestive heart failure NYHA Class 3 or 4, hypertension BP\>150/100mmHg. * Pre-diagnosed diabetes mellitus. * Fasting glucose \> 7.0 mmol/L or HbA1c \> 6%.